Pharmaceuticals News and Research

RSS

Shire receives Paragraph IV Notice Letter from Zydus over filing of ANDA for generic LIALDA

Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter today from Zydus Pharmaceuticals USA, Inc. advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1.2g mesalamine delayed release tablets, LIALDA(R).

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

VaxGen, Inc., a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger.

29 May 2010

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

GE Healthcare, a unit of General Electric Company, today announced that the US Food and Drug Administration has approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.

29 May 2010

Neptune's revenues increased by 8% for fiscal year ended February 28, 2010

Neptune Technologies & Bioressources Inc. today reports its consolidated financial results for the fiscal year ended February 28, 2010, announces the implementation of a shareholder rights plan and provides fiscal year highlights.

28 May 2010

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Relevare Pharmaceuticals Ltd. will present its recent Phase IIa proof-of-concept clinical trial data and extension study results for CNSB015 (flupirtine), its lead repositioned compound, at the Third International Congress on Neuropathic Pain on May 27 –30 in Athens, Greece.

28 May 2010

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the expansion of its collaboration with the U.S. Government to include the evaluation of Restanza's activity against sexually transmitted infections (STI's), such as gonorrhea.

28 May 2010

VIVUS first-quarter 2010 total revenues decline: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring VIVUS Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

28 May 2010

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

Nymox Pharmaceutical Corporation is pleased to announce the presenters and participants for the symposium and panel discussion on NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), to be held during the 2010 Annual Meeting of the American Urological Association in San Francisco at 3:00 p.m. June 1.

28 May 2010

Researchers see plectasin as promising lead compound for new antibiotics

An active compound from fungi and lower animals may well be suitable as an effective weapon against dangerous bacteria. We're talking about plectasin, a small protein molecule that can even destroy highly resistant bacteria . Researchers at the Universities of Bonn, Utrecht, Aalborg and of the Danish company Novozymes AS have shed light on how the substance does this.

28 May 2010

CrystalGenomics to merge with BexPharm

CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.

28 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

Wall Street Journal examines GSK's open-source development for drug discovery plan

The Wall Street Journal examines GlaxoSmithKline's plan to share its database of compounds that could treat tropical diseases. The initiative will test how well "open-source principles work for developing new drugs," the newspaper reports.

28 May 2010

NeoStem to present adult stem cell technologies at Stem Cell Investor & Executive Networking Conference

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced that the Company has been invited to present its adult stem cell technologies at the Stem Cell Investor & Executive Networking Conference Event (SCIENCE) in New York City on June 1, 2010. SCIENCE is designed to bring together investors with industry executives, visionary researchers and clinicians and other stakeholders to highlight opportunities and discuss advances in the stem cell field.

28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

IPS Research joins SAFE-BioPharma Association

IPS Research Company, a major southwest clinical research investigator site located in Oklahoma City, OK, has joined SAFE-BioPharma Association and taken another step in the process of eliminating paper copies from its operations.

28 May 2010

New study examines internal and external uses of health outcomes data for promotional purposes

Health outcomes data can be an important promotional/commercial tool for the biopharma industry, but approaches differ company to company as the marketplace continues to evolve. A new study by Best Practices, LLC examines internal and external uses of health outcomes data for promotional purposes.

28 May 2010

Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a new analysis of data from its Phase 3 (FAME) clinical trials for Iluvien, the company's investigational intravitreal insert being studied for diabetic macular edema (DME), indicates that patient vision continues to improve significantly over 30 months.

28 May 2010

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

In an effort to meet the rising rates of melanoma head-on, The Wistar Institute today announced the creation of The Wistar Institute Melanoma Research Center. The Center brings together scientists, physicians, the life sciences industry, and melanoma advocates in saving lives by advancing new and better therapies for this deadly disease.

28 May 2010

InNexus Biotechnology announces research Collaboration Agreement with National Cancer Institute

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to research proprietary technologies developed by InNexus.

28 May 2010

Pharmaceuticals News and Research

Shire receives Paragraph IV Notice Letter from Zydus over filing of ANDA for generic LIALDA

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

Neptune's revenues increased by 8% for fiscal year ended February 28, 2010

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

VIVUS first-quarter 2010 total revenues decline: MicroStockProfit.com

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

Researchers see plectasin as promising lead compound for new antibiotics

CrystalGenomics to merge with BexPharm

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Wall Street Journal examines GSK's open-source development for drug discovery plan

NeoStem to present adult stem cell technologies at Stem Cell Investor & Executive Networking Conference

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

IPS Research joins SAFE-BioPharma Association

New study examines internal and external uses of health outcomes data for promotional purposes

Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

InNexus Biotechnology announces research Collaboration Agreement with National Cancer Institute

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News